

Table S1. Locoregional recurrence (n=171).

Variables	Number (n)	2-year locoregional recurrence rate (%)	Univariate analysis		Multivariate analysis				
			HR	95% CI	P-value	HR _{adj}	95% CI	P-value	
Patient subgroups									
Non-HIV vs. ART-naïve	123 vs. 25	78 vs. 69	0.90	(0.34-2.37)	0.837	0.95	(0.36-2.5)	0.913	
ART-treated vs. ART-naïve	23 vs. 25	100 vs. 69	0.15	(0.02-1.32)	0.088	0.24	(0.03-2.13)	0.201	
ART-treated vs. non-HIV	23 vs. 123	100 vs. 78	0.17	(0.02-1.27)	0.084	0.26	(0.03-1.94)	0.187	
Age (years)									
<60 vs. ≥60	126 vs. 45	78.7 vs. 84.9	0.81	(0.33-1.97)	0.636				
Histology									
SCC vs. adeno	150 vs. 21	81.5 vs. 72.3	1.75	(0.71-4.29)	0.221				
Tumor size (cm)									
<4 vs. ≥4	39 vs. 132	80.3 vs. 79.6	0.90	(0.4-02.02)	0.789				
FIGO stage									
Stage IB2-IIB vs. stage IIIA-IVA	108 vs. 63	87 vs. 64.7	2.55	(1.23-5.28)	0.012	1.74	(0.80-3.78)	0.160	
Parametrial invasion									
Absent vs. present	38 vs. 133	83 vs. 78.8	1.21	(0.52-2.84)	0.658				
Metastatic lymph node									
Absent vs. present	125 vs. 46	83.6 vs. 70.9	1.63	(0.77-3.45)	0.197				
Treatment									
CTRT vs. radical RT	166 vs. 5	79.3 vs. 100							
PDL1 expression									
Negative vs. positive	41 vs.130	88 vs. 77.7	1.66	(0.63-4.34)	0.302				
PDL1 copy number alterations									
Polysomy vs. disomy	60 vs. 99	65.6 vs. 89.7	3.46	(1.61-7.45)	0.002	2.50	(1.11-5.63)	0.027	
Amplification vs. disomy	12 vs. 99	75 vs. 89.7	1.73	(0.22-13.67)	0.601	1.44	(0.18-11.41)	0.733	

ART, antiretroviral therapy; SCC, squamous cell carcinoma; Adeno, adenocarcinoma; FIGO, International Federation of Gynecology and Obstetrics; CTRT, concurrent chemoradiotherapy; RT, radiation therapy; PD-L1, programmed cell death ligand 1; HR, hazard ratio; CI, confidence interval.

Table SII. Recurrence-free survival (n=171).

Variables	Number (n)	2-year locoregional recurrence rate (%)	Univariate analysis			Multivariate analysis		
			HR	95% CI	P-value	HR _{adj}	95% CI	P-value
Patient subgroups								
Non-HIV vs. ART-untreated	123 vs. 25	51.8 vs. 56.7	0.90	(0.48-1.7)	0.755	1.07	(0.55-2.09)	0.833
ART-treated vs. ART-untreated	23 vs. 25	84.9 vs. 56.7	0.44	(0.17-1.11)	0.081	0.64	(0.22-1.85)	0.415
ART-treated vs. non-HIV	23 vs. 123	84.9 vs. 51.8	0.48	(0.22-1.07)	0.073	0.60	(0.24-1.47)	0.265
Age (years)								
<60 vs. ≥60	126 vs. 45	58.4 vs. 56.4	0.95	(0.54-1.67)	0.872			
Histology								
SCC vs. adeno	150 vs. 21	57 vs. 66.6	0.92	(0.44-1.92)	0.817			
Tumor size (cm)								
<4 vs. ≥4	39 vs. 132	76.8 vs. 51.5	2.30	(1.17-4.52)	0.016	1.42	(0.69-2.95)	0.344
FIGO stage								
Stage IB2-IIB vs. stage IIIA-IVA	108 vs. 63	70.3 vs. 30.5	2.87	(1.76-4.69)	<0.001	2.43	(1.37-4.30)	0.002
Parametrial invasion								
Absent vs. present	38 vs. 133	75.6 vs. 52.1	1.97	(1.05-3.71)	0.035	0.81	(0.37-1.77)	0.601
Metastatic lymph node								
Absent vs. present	125 vs. 46	64.8 vs. 39.5	1.98	(1.20-3.27)	0.007	1.35	(0.79-2.32)	0.274
Treatment								
CTRT vs. radical RT	166 vs. 5	56.1 vs. 100						
PDL1 expression								
Negative vs. positive	41 vs. 130	75.4 vs 52.3	1.78	(0.95-3.34)	0.071	0.85	(0.40-1.83)	0.682
PDL1 copy number alterations								
Polysomy vs. disomy	60 vs. 99	45.9 vs. 70.6	2.39	(1.44-3.99)	0.001	1.73	(0.96-3.12)	0.067
Amplification vs. disomy	12 vs. 99	22.2 vs. 70.6	8.37	(3.67-19.12)	<0.001	7.03	(2.79-17.74)	<0.001

ART, antiretroviral therapy; SCC, squamous cell carcinoma; Adeno, adenocarcinoma; FIGO, International Federation of Gynecology and Obstetrics; CTRT, concurrent chemoradiotherapy; RT, radiation therapy; PD-L1, programmed cell-death ligand 1; HR, hazard ratio; CI, confidence interval.

Table SIII. Cancer-specific survival (n=171).

Variables	Number (n)	2-year locoregional recurrence rate (%)	Univariate analysis			Multivariate analysis		
			HR	95% CI	P-value	HR _{adj}	95% CI	P-value
Patient subgroups								
Non-HIV vs. ART-naïve	123 vs. 25	76.4 vs. 68	0.72	(0.34-1.52)	0.388	1.09	(0.49-2.42)	0.826
ART-treated vs. ART-naïve	23 vs. 25	90.5 vs. 68	0.21	(0.04-0.96)	0.044	0.55	(0.12-2.63)	0.455
ART-treated vs. non-HIV	23 vs. 123	90.5 vs. 76.4	0.29	(0.07-1.20)	0.087	0.50	(0.12-2.20)	0.362
Age (years)								
<60 vs. ≥60	126 vs. 45	79.4 vs. 70.8	1.45	(0.77-2.76)	0.251			
Histology								
SCC vs. adeno	150 vs. 21	75.7 vs. 88.2	0.49	(0.15-1.59)	0.237			
Tumor size (cm)								
<4 vs. ≥4	39 vs. 132	94.3 vs. 72.4	6.79	(1.64-28.08)	0.008	2.39	(0.55-10.42)	0.245
FIGO stage								
Stage IB2-IIB vs. stage IIIA-IVA	108 vs. 63	94.8 vs. 49.5	14.73	(6.18-35.09)	<0.001	11.47	(4.70-27.99)	<0.001
Parametrial invasion								
Absent vs. present	38 vs. 133	100 vs. 71						
Metastatic lymph node								
Absent vs. present	125 vs. 46	83 vs. 63.4	2.19	(1.19-4.03)	0.012	1.46	(0.77-2.77)	0.246
Treatment								
CTRT vs. radical RT	166 vs. 5	76.5 vs. 100						
PDL1 expression								
Negative vs. positive	41 vs. 130	77.9 vs. 77.1	1.25	(0.60-2.61)	0.550			
PDL1 copy number alterations								
Polysomy vs. disomy	60 vs. 99	75.1 vs. 84.6	2.08	(1.07-4.05)	0.031	0.92	(0.45-1.87)	0.815
Amplification vs. disomy	12 vs. 99	31.3 vs. 84.6	7.46	(3.15-17.69)	<0.001	4.05	(1.64-9.98)	0.002

ART, antiretroviral therapy; SCC, squamous cell carcinoma; adeno, adenocarcinoma; FIGO, International Federation of Gynecology and Obstetrics; CTRT, concurrent chemoradiotherapy; RT, radiation therapy; PD-L1, programmed cell death ligand 1; HR, hazard ratio; CI, confidence interval.